Leucocyte depletion of perioperative blood transfusion does not affect long-term survival and recurrence in patients with gastrointestinal cancer

Lange, Marilyne M.; Hilten, J. A. van; Watering, Leo M.G. van de; Bijnen, Bart; Roumen, R. M. H.; Putter, Hein; Brand, Anneke; Velde, Cornelis J.H. van de

doi:10.1002/bjs.6636

Cited by 32 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, recent animal studies have proposed that old red blood cells, rather than leukocyctes or soluble fractions, are responsible for the tumor‐promoting effects of both autologous and allogeneic blood transfusions . This was proven in demonstrating that neither allogeneic nor autologous blood treated with leukocyte‐depletion filtration affected cancer recurrence in patients undergoing oncological surgeries …”

Section: Discussionmentioning

confidence: 99%

Perioperative blood transfusion: does it influence survival and cancer progression in metastatic spine tumor surgery?

et al. 2016

View full text Add to dashboard Cite

This is the first study providing evidence that disease progression and survival in patients who undergo MSTS are less likely to be influenced by perioperative ABT. The worst oncologic outcomes are more likely to be caused by the clinical circumstances necessitating blood transfusion, but not transfusion itself. However, because ABT can have a propensity toward developing postoperative infections, including surgical site infection, the use of patient blood management interventions would be worthwhile rather than relying solely on ABTs for these patients, if and whenever possible.

show abstract

Section: Discussionmentioning

confidence: 99%

Perioperative blood transfusion: does it influence survival and cancer progression in metastatic spine tumor surgery?

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The administration of peri‐operative blood transfusions (PBT) has been associated with prognosis in several organ‐specific cancers, including oesophageal, gastric, colorectal and hepatic carcinomas . It has been suggested that immunosuppressive mechanisms in the PBT recipient have an impact on cancer‐related outcomes owing to the large amounts of antigen in transfused blood products.…”

Section: Introductionmentioning

confidence: 99%

Impact of peri‐operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder

et al. 2014

View full text Add to dashboard Cite

Objective• To determine the association between peri-operative blood transfusion (PBT) and oncological outcomes in a large multi-institutional cohort of patients undergoing radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB). Patients and Methods• We conducted a retrospective analysis of 2895 patients treated with RC for UCB. • Univariable and multivariable Cox regression models were used to analyse the effect of PBT administration on disease recurrence, cancer-specific mortality, and any-cause mortality. Results• Patients' median (interquartile range [IQR]) age was 67 (60, 73) years and the median (IQR) follow-up was 36.1 (15, 84) months.• Patients who received PBT were more likely to have advanced disease (P < 0.001), high grade tumours (P = 0.047) and nodal metastasis (P = 0.004).• PBT was associated with a higher risk of disease recurrence (P = 0.003), cancer-specific mortality (P = 0.017), and any-cause mortality (P = 0.010) in univariable, but not multivariable, analyses (P > 0.05).• In multivariable analyses, pathological tumour stage, pathological nodal stage, soft tissue surgical margin, lymphovascular invasion and administration of adjuvant chemotherapy were independent predictors of disease recurrence, cancer-specific mortality and any-cause mortality (all P values <0.002). Conclusions• Patients with UCB who underwent RC and received PBT had a greater risk of disease recurrence, cancer-specific mortality and any-cause mortality in univariable, but not multivariable, analysis.• Although the greater need for PBT with more advanced disease is probably caused by a number of factors, including surgical and cancer-related factors, the present analysis showed that the disease characteristics rather than need for PBT led to worse outcomes.

show abstract

“…The nonsignificant and small RR of colorectal cancer recurrence secondary to nonleukoreduced ABT across the three RCTs dampened the enthusiasm for investigating this purported ABT effect by means of RCTs and also by means of observational studies. Between patients with gastric cancer randomly assigned to receive nonleukoreduced versus leukoreduced ABT, there was no difference in survival or cancer recurrence . Observational studies continued to generate debate by sometimes reporting significant associations of nonleukoreduced ABT with cancer recurrence, cancer‐specific mortality, and/or all‐cause mortality, until two recent meta‐analyses of ABT and adverse clinical outcomes in colorectal cancer and hepatocellular cancer resurrected the controversy about a purported adverse ABT effect.…”

mentioning

confidence: 99%

Allogeneic blood transfusion and cancer recurrence: 20 years later

Vamvakas¹

2014

Transfusion

View full text Add to dashboard Cite

Leucocyte depletion of perioperative blood transfusion does not affect long-term survival and recurrence in patients with gastrointestinal cancer

Abstract: Leucocyte depletion is not associated with better long-term survival and lower recurrence rates in patients with gastrointestinal cancer.

Cited by 32 publications

References 18 publications

Perioperative blood transfusion: does it influence survival and cancer progression in metastatic spine tumor surgery?

Perioperative blood transfusion: does it influence survival and cancer progression in metastatic spine tumor surgery?

Impact of peri‐operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder

Allogeneic blood transfusion and cancer recurrence: 20 years later

Contact Info

Product

Resources

About